Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc.

NASDAQ:MBRX

Overview | Financials
Company Name Moleculin Biotech, Inc.
Symbol MBRX
Currency USD
Price 2.36
Market Cap 6,713,091
Dividend Yield 0%
52-week-range 0.4 - 6.24
Industry Biotechnology
Sector Healthcare
CEO Mr. Walter V. Klemp
Website https://www.moleculin.com

An error occurred while fetching data.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to

Related Stocks

Applied Therapeutics, Inc. logo

Applied Therapeutics, Inc.

APLT

8.63 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

2.14 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

2.04 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

1.15 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

7.5 USD

Financials

Numbers are in millions USD

Numbers are in millions USD